- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla reports bigger-than-expected rise in Q2 profit
Higher market share in cancer drugs Revlimid and Lanreotide and lower price erosion have helped Cipla's sales in the North American market, analysts said.
Bengaluru: Cipla, India’s third-largest generic drugmaker by sales, posted a bigger-than-expected rise in second-quarter profit, boosted by strength in its key domestic and North American business.
Total revenue from operations rose nearly 15% to 66.78 billion rupees, led by a 13.4% growth in its mainstay pharmaceutical business, said Cipla, which makes generic respiratory and cancer drugs along with consumer-branded products such as pain reliever Omnigel.
Sales in North America climbed nearly 32%, while its other key markets including India and South Africa posted a 10% and 3.7% growth, respectively.
Higher market share in cancer drugs Revlimid and Lanreotide and lower price erosion have helped Cipla’s sales in the North American market, analysts said.
“The strong Cipla numbers have set a positive tone for the large pharma results for the remainder of the quarter,” said Shrikant Akolkar, an analyst at Asian Markets Securities, adding that gross margins also benefitted from falling raw material costs.
Meanwhile, its domestic sales were boosted by price hikes and the addition of medical representatives, who promote and sell pharmaceutical products to healthcare professionals.
Cipla’s founding family has been keen to sell their 33.4% holding entirely.
India’s Torrent Pharmaceuticals are in talks with private equity funds, including CVC Capital Partners and Bain Capital, to raise up to $1.5 billion to bid for Cipla, Reuters reported last month.
Read also: Torrent Pharma in discussions with Apollo to borrow up to USD 1 billion for Cipla bid: Sources
If the deal works out, it would be the largest in the Indian pharma sector, analysts said.
Cipla’s shares jumped as much as 4.1% after the results and were up 1.9%, as of 3:20 p.m. IST.
They have risen nearly 17% in the September quarter, compared with a 12% rise in the Nifty Pharma index.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751